Tiziana Pia L.
- Country
- Italy
- Department
- Oncology
Research Overview
- Pumitamig and Combination Therapy Versus Bevacizumab and Combination Therapy in Previously Untreated, Unresectable, or Metastatic Colorectal Cancer
- Phase 3 Randomized Double-Blind Study of INCA33890 Plus First-Line Chemotherapy and Bevacizumab in Metastatic Microsatellite Stable Colorectal Cancer
- Switch Maintenance with Paclitaxel, Ramucirumab and Tislelizumab vs Continued Chemotherapy plus Tislelizumab in HER2‑negative, PD‑L1‑positive Gastroesophageal Adenocarcinoma
Data & Insights
Has run more than one trial at 161 of 395 partner sites.
Specializations
Colorectal Cancer Treatment Innovation
This investigator specializes in developing advanced treatment strategies for metastatic colorectal cancer, with particular focus on targeted therapies and molecular-guided approaches.
- RAS/BRAF mutation analysis
- EGFR-targeted therapies
- Sequential treatment strategies
Primary expertise includes personalized treatment sequencing and biomarker-driven therapy selection.
Precision Medicine Applications
The investigator leads research in circulating tumor DNA (ctDNA) applications for both treatment monitoring and therapy selection in colorectal cancer patients.
- Post-operative treatment optimization
- Molecular-guided therapy selection
- Treatment response monitoring
Focuses on implementing liquid biopsy technologies to guide clinical decision-making.
Gastrointestinal Oncology
Expertise extends to treating various stages of gastrointestinal cancers, including advanced gastric and gastroesophageal junction malignancies.
- Immunotherapy combinations
- Novel antibody therapeutics
- Stage-specific treatment protocols
Specializes in combining targeted therapies with conventional treatment approaches.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.